Table 1.
Clinicopathologic characteristics of patients treated with ultra-early or early salvage ADT
| Variable | Ultra-early salvage ADT(n = 51) | Early salvage ADT(n = 70) | p-value |
|---|---|---|---|
| Median age at prostatectomy, yr (IQR) | 65 (61 - 69) | 67 (60.75 - 72.25) | 0.2992 |
| Age at prostatectomy, no. (%): | 0.0804 | ||
| <70 yr | 39 (76.5) | 43 (61.4) | |
| ≥70 yr | 12 (23.5) | 27 (38.6) | |
| Median preoperative PSA, ng/ml (IQR) | 10.65 (7.3 - 15.56) | 9.55 (6.3 - 12.07) | 0.1903 |
| Preoperative PSA, no (%): | 0.6041 | ||
| <20 ng/ml | 46 (90.2) | 61 (87.1) | |
| ≥20 ng/ml | 5 (9.8) | 9 (12.9) | |
| Pathologic Gleason score, no. (%): | 0.3256 | ||
| ≤6 | 12 (23.5) | 23 (32.9) | |
| 7 | 28 (54.9) | 38 (54.3) | |
| 8-10 | 11 (21.6) | 9 (12.9) | |
| Pathologic tumor stage, no. (%): | 0.8619 | ||
| T2 | 32 (62.7) | 45 (64.3) | |
| T3/4 | 19 (37.3) | 25 (35.7) | |
| Extraprostatic extension, no. (%) | 17 (33.3) | 25 (35.7) | 0.7859 |
| Lymphovascular invasion, no. (%) | 13 (25.5) | 16 (22.9) | 0.7376 |
| Positive resection margin, no. (%) | 37 (72.5) | 43 (61.4) | 0.2019 |
| Seminal vesicle invasion, no. (%) | 2 (3.9) | 2 (2.9) | 0.7464 |
| Perineural invasion, no. (%) | 35 (68.6) | 43 (61.4) | 0.4139 |
| Median duration time of salvage ADT, months (IQR) | 41 (22 - 66) | 46 (27 - 73.25) | 0.1326 |
ADT, androgen deprivation therapy; PSA, prostate-specific antigen; IQR, interquartile range.